AVN 322

Drug Profile

AVN 322

Alternative Names: AVN-322

Latest Information Update: 12 Sep 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ChemDiv
  • Developer AllaChem; Avineuro Pharmaceuticals
  • Class Nootropics; Pyrimidines; Small molecules
  • Mechanism of Action Serotonin 6 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Alzheimer's disease

Most Recent Events

  • 12 Sep 2016 Phase-II clinical trials in Alzheimer's disease in USA before September 2016 (Spring Bank Pharmaceuticals pipeline, September 2016)
  • 13 Nov 2013 Phase-I development is ongoing in USA
  • 13 Nov 2013 AVN 322 sublicensed to AllaChem before Nov 2013
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top